08:47 AM EDT, 10/03/2024 (MT Newswires) -- Spectral Medical ( EDTXF ) , a theranostic company advancing therapeutic options for sepsis and septic shock, on Thursday provided an update on its Tigris trial, a phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion in a randomized controlled trial of adults treated for endotoxemia and septic shock.

The company said robust enrollment continues for 2024, with 132 patients enrolled at end of September. With 18 patients to target enrollment, Spectral said it has entered the final push to fully enroll and finish the Tigris trial, which it expects to happen by the end of the year.

"We continue to enjoy very strong activity at our sites," said John Kellum, Spectral's chief medical officer. "As such, we remain confident in finalizing full Tigris enrollment around year end 2024."